RxDoctor Payments DataLook up a doctor →

Kristi Glanzer

Nurse Practitioner · Huron, SDNPI 1245232008

Payments from drug & device makers

$6,215in general payments, 2019–2025

Across 452 payments — averaging $13.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$870
  • Novo Nordisk$703
  • Pfizer$579
  • Amgen$470
  • Grifols USA, LLC$389
  • AbbVie$353
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$6,10998%
  • Education$1072%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,215 in reported general payments places this provider in the 95th percentile of 504 nurse practitioner providers in South Dakota.

See all nurse practitioner providers in South Dakota

Medicare billing

Part B allowed, 2024
$323,686
Medicare patients
309
Services billed
12,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide163$173,328
OzempicSemaglutide103$109,535
EliquisApixaban77$74,587
JardianceEmpagliflozin70$56,441
TrulicityDulaglutide55$54,285
FarxigaDapagliflozin Propanediol64$52,134
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$37,708
XareltoRivaroxaban41$33,614
Nurtec OdtRimegepant Sulfate16$22,094
OxycontinOxycodone Hcl13$18,740
LinzessLinaclotide32$17,190
EntrestoSacubitril/Valsartan17$15,372
MyrbetriqMirabegron20$14,798
Breo ElliptaFluticasone/Vilanterol15$11,216
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$6,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$870$227,612218 claims
Novo NordiskOzempic$703$109,535103 claims
PfizerEliquis, Nurtec Odt$579$96,68193 claims
Boehringer IngelheimJardiance$309$56,44170 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$156$54,99775 claims
AstraZenecaFarxiga$309$52,13464 claims
Johnson & JohnsonXarelto$333$33,61441 claims
AbbVieLinzess$353$17,19032 claims
NovartisEntresto$219$15,37217 claims
Astellas Pharma US IncMyrbetriq$291$14,79820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 504 nurse practitioner providers in South Dakota.

Other nurse practitioner in Huron

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →